IL263059B2 - Compounds containing a ligand for the folate receptor for use in a method of treating cancer, the inventions being directed to cells that are MYELOID–DERIVED SUPPRESSOR CELLS - Google Patents

Compounds containing a ligand for the folate receptor for use in a method of treating cancer, the inventions being directed to cells that are MYELOID–DERIVED SUPPRESSOR CELLS

Info

Publication number
IL263059B2
IL263059B2 IL263059A IL26305918A IL263059B2 IL 263059 B2 IL263059 B2 IL 263059B2 IL 263059 A IL263059 A IL 263059A IL 26305918 A IL26305918 A IL 26305918A IL 263059 B2 IL263059 B2 IL 263059B2
Authority
IL
Israel
Prior art keywords
cancer
compounds
folate receptor
drug
cells
Prior art date
Application number
IL263059A
Other languages
English (en)
Hebrew (he)
Other versions
IL263059B1 (en
IL263059A (en
Original Assignee
Purdue Research Foundation
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte Inc filed Critical Purdue Research Foundation
Publication of IL263059A publication Critical patent/IL263059A/en
Publication of IL263059B1 publication Critical patent/IL263059B1/en
Publication of IL263059B2 publication Critical patent/IL263059B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
IL263059A 2016-05-25 2017-05-25 Compounds containing a ligand for the folate receptor for use in a method of treating cancer, the inventions being directed to cells that are MYELOID–DERIVED SUPPRESSOR CELLS IL263059B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341587P 2016-05-25 2016-05-25
PCT/US2017/034537 WO2017205661A1 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells

Publications (3)

Publication Number Publication Date
IL263059A IL263059A (en) 2018-12-31
IL263059B1 IL263059B1 (en) 2024-10-01
IL263059B2 true IL263059B2 (en) 2025-02-01

Family

ID=60412652

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263059A IL263059B2 (en) 2016-05-25 2017-05-25 Compounds containing a ligand for the folate receptor for use in a method of treating cancer, the inventions being directed to cells that are MYELOID–DERIVED SUPPRESSOR CELLS

Country Status (8)

Country Link
US (2) US20190216935A1 (enExample)
EP (1) EP3463367A4 (enExample)
JP (1) JP7278777B2 (enExample)
KR (1) KR102489277B1 (enExample)
CN (2) CN109475558A (enExample)
AU (1) AU2017271550B2 (enExample)
IL (1) IL263059B2 (enExample)
WO (1) WO2017205661A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108710A1 (en) * 2018-08-07 2020-02-13 Purdue Research Foundation Rejuvenation of car t cell
AU2020310141A1 (en) 2019-07-08 2022-02-03 Purdue Research Foundation Compounds and methods for the treatment and prevention of fibrotic disease states and cancer
AU2021305193A1 (en) * 2020-07-08 2023-02-09 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
KR20240140961A (ko) * 2022-03-08 2024-09-24 주식회사 코넥스트 콜라게네이즈, 칼슘, 히스티딘 및 글리신를 포함하는 조성물 및 콜라게네이즈의 안정화 방법
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062697A2 (en) * 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279304A1 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
BR112012002064A2 (pt) * 2009-07-31 2017-05-09 Endocyte Inc método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele
CA2793657A1 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
EP2701722A4 (en) * 2011-04-28 2014-12-31 Univ Southern California Human myeloid derived suppressor cell cancer markers
US9550992B2 (en) * 2011-12-02 2017-01-24 University Of South Florida Compositions and methods for modulating myeloid derived suppressor cells
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
SG11201607705XA (en) * 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20170266303A1 (en) * 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) * 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062697A2 (en) * 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERRIT JANSEN ET AL,, NOVEL INSIGHTS IN FOLATE RECEPTORS AND TRANSPORTERS: IMPLICATIONS FOR DISEASE AND TREATMENT OF IMMUNE DISEASES AND CANCER, 1 January 2015 (2015-01-01) *
JIAYIN SHEN,, FOLATE RECEPTOR BETA: A NEW SURFACE MOLECULE FOR SELECTIVE TARGETING OF ACTIVATED MACROPHAGES IN INFLAMMATORY DISEASES AND CANCER DOCTOR OF PHILOSOPHY, 1 May 2013 (2013-05-01) *
THESES ET AL,, UNIVERSITY OF WISCONSIN MILWAUKEE UWM DIGITAL COMMONS MIGRATION OF MYELOID-DERIVED SUPPRESSOR CELLS TO TUMOR AND TUMOR-DRAINING LYMPH NODE IN A MURINE MODEL OF BREAST CANCER RECOMMENDED CITATION MATSON, VYARA, " MIGRATION OF MYELOID-DERIVED SUPPRESSO, 1 January 2015 (2015-01-01) *

Also Published As

Publication number Publication date
KR20190021261A (ko) 2019-03-05
CN109475558A (zh) 2019-03-15
IL263059B1 (en) 2024-10-01
JP2019519524A (ja) 2019-07-11
IL263059A (en) 2018-12-31
AU2017271550A1 (en) 2018-12-06
RU2018145750A (ru) 2020-06-25
EP3463367A1 (en) 2019-04-10
RU2018145750A3 (enExample) 2020-07-30
NZ748427A (en) 2025-05-30
CN114903890A (zh) 2022-08-16
US20210170035A1 (en) 2021-06-10
AU2017271550B2 (en) 2023-11-02
WO2017205661A1 (en) 2017-11-30
KR102489277B1 (ko) 2023-01-16
EP3463367A4 (en) 2020-01-29
US20190216935A1 (en) 2019-07-18
JP7278777B2 (ja) 2023-05-22
BR112018074119A2 (pt) 2019-03-06
CA3025309A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
US20210170035A1 (en) Method of treating cancer by targeting myeloid-derived suppressor cells
JP2024114976A (ja) がんの処置のための併用療法
CA2484640C (en) Vitamin-mitomycin conjugates
US20240415921A1 (en) Methods of treating cancer by targeting tumor-associated macrophages
AU2004210136B2 (en) Vitamin receptor binding drug delivery conjugates
US20230241227A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
CN102215844A (zh) 抗叶酸剂的叶酸受体结合轭合物
US20140171433A1 (en) Multiple myeloma treatment
US20160166679A1 (en) Method of treatment using folate conjugates and tyrosine kinase inhibitors
US20200038514A1 (en) Folate conjugate for use in targeting tumor associated macrophages
US11981672B2 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
CA3025309C (en) Method of treating cancer by targeting myeloid-derived suppressor cells
RU2776899C2 (ru) Способ лечения рака нацеливанием на супрессорные клетки миелоидного происхождения
US20230285556A1 (en) Methods and compositions for treating cancer
BR112018074119B1 (pt) Uso de compostos compreendendo um ligante de ligação de receptor folato ligado a um fármaco via um ligante, e composição farmacêutica
WO2023039603A2 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
US20240382603A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
CA3181254A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
CN110678204A (zh) 用于靶向肿瘤相关巨噬细胞的叶酸缀合物
WO2024102810A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor